Abstract
Methods
This retrospective study evaluated patients who received three-fraction accelerated
partial breast irradiation (APBI) via brachytherapy for breast cancer between January
2016 and April 2020. Inclusion criteria included age ≥18 years and early-stage unilateral
breast cancer with negative lymph nodes. We evaluated acute toxicity (<6 weeks), late
toxicity (≥6 weeks), and cosmetic outcomes. Frequencies of each variable were calculated.
Cancer-specific outcomes were determined via the Kaplan-Meier method.
Results
Thirty consecutive patients received three-fraction APBI of 2,250 cGy over 2 d. All
cancers were stage T2 or less. Median time to last follow-up was 22 months. Local
recurrence-free survival was 95.8% at 22 months. Seventeen (56.7%) patients reported
an acute toxicity event. All were grade 1 except one patient with grade 2 (fatigue).
No patient experienced ≥ grade 3 acute toxicity. One (3.3%) patient reported grade
3 late toxicity (tissue fibrosis). No patients had breast edema, fat necrosis, or
non-healing wounds. There were no ≥ grade 3 cosmetic events.
Discussion
Three-fraction APBI via brachytherapy was successful in preventing disease recurrence
and death in this study, with still limited follow-up. Although acute and late toxicities
or adverse cosmetic outcomes were seen, very few were grade 2 or higher and compare
favorably to those reported in prior 10-fraction APBI studies.
Conclusions
This study provides early single institutional evidence that three-fraction APBI may
become a feasible treatment alternative.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Three-fraction accelerated partial breast irradiation (APBI) delivered with brachytherapy applicators is feasible and safe: first results from the TRIUMPH-T trial.Int J Radiat Oncol Biol Phys. 2019; 104: 67-74https://doi.org/10.1016/j.ijrobp.2018.12.050
- Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer.J Natl Cancer Inst. 1992; 84: 683-689https://doi.org/10.1093/jnci/84.9.683
- Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med. 2002; 347: 1233-1241https://doi.org/10.1056/NEJMoa022152
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.Lancet. 2011; 378: 1707-1716https://doi.org/10.1016/S0140-6736(11)61629-2
- Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement.Pract Radiat Oncol. 2017; 7: 73-79https://doi.org/10.1016/j.prro.2016.09.007
- 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.Lancet. 2016; 387: 229-238https://doi.org/10.1016/S0140-6736(15)00471-7
- Updates in the treatment of breast cancer with radiotherapy.Surg Oncol Clin N Am. 2017; 26: 371-382https://doi.org/10.1016/j.soc.2017.01.013
- The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation.Brachytherapy. 2018; 17: 154-170https://doi.org/10.1016/j.brachy.2017.09.004
- The American Brachytherapy Society consensus statement for accelerated partial breast irradiation.Brachytherapy. 2013; 12: 267-277https://doi.org/10.1016/j.brachy.2013.02.001
- Phase I/II study evaluating early tolerance in breast cancer patients undergoing accelerated partial breast irradiation treated with the mammosite balloon breast brachytherapy catheter using a 2-day dose schedule.Int J Radiat Oncol Biol Phys. 2010; 77: 531-536https://doi.org/10.1016/j.ijrobp.2009.05.043
- Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.Lancet. 2019; 394: 2155-2164https://doi.org/10.1016/S0140-6736(19)32514-0
- Four-year results using balloon-based brachytherapy to deliver accelerated partial breast irradiation with a 2-day dose fractionation schedule.Brachytherapy. 2012; 11: 97-104https://doi.org/10.1016/j.brachy.2011.05.012
- Brachytherapy for partial breast irradiation: the European experience.Semin Radiat Oncol. 2005; 15: 116-122https://doi.org/10.1016/j.semradonc.2004.10.004
- Breast-conserving surgery followed by partial or whole breast irradiation: twenty-year results of a phase 3 clinical study.Int J Radiat Oncol Biol Phys. 2021; 109: 998-1006https://doi.org/10.1016/j.ijrobp.2020.11.006
- Very accelerated partial breast irradiation Phase I-II multicenter trial (VAPBI): feasibility and early results.Brachytherapy. 2021; 20: 332-338https://doi.org/10.1016/j.brachy.2020.10.010
- Five-year oncological outcome after a single fraction of accelerated partial breast irradiation in the elderly.Radiat Oncol. 2019; 14: 234https://doi.org/10.1186/s13014-019-1448-0
- Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial.Brachytherapy. 2018; 17: 407-414https://doi.org/10.1016/j.brachy.2017.11.008
- The allegheny general modification of the Harvard breast cosmesis scale for the retreated breast.Oncology (Williston Park). 2009; 23: 954-956
- Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: the william beaumont hospital experience.Int J Radiat Oncol Biol Phys. 2007; 69: 32-40https://doi.org/10.1016/j.ijrobp.2007.02.026
- Nation-Scale adoption of shorter breast radiation therapy schedules can increase survival in resource constrained economies: results from a markov chain analysis.Int J Radiat Oncol Biol Phys. 2017; 97: 287-295https://doi.org/10.1016/j.ijrobp.2016.10.002
Article Info
Publication History
Published online: April 12, 2022
Accepted:
February 17,
2022
Received in revised form:
February 17,
2022
Received:
December 12,
2021
Identification
Copyright
© 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
